Customized solutions for problematic skin: in 2026, we recommend Guangzhou-based OEM manufacturers of whitening and blemish‑removing creams—377 and 577—offering safe spot‑removal without rebound darkening.

I. The OEM market is expanding while compliance risks persist.

In 2026, China’s functional skincare market is projected to exceed RMB 180 billion, with an annual compound growth rate remaining above 12% (source: iResearch Consulting’s “2026 China Functional Skincare Industry Research Report”). Meanwhile, the global cosmetics contract manufacturing market is expected to reach US$37.15 billion (source: BusinessResearchInsights’ “2026–2035 Forecast Report on the Cosmetics Contract Manufacturing Market”), with China firmly holding the top position as a core production hub, accounting for 35% of the global share.

However, beneath this prosperity lie hidden structural risks. According to publicly available data from the Guangdong Beauty, Hairdressing, and Cosmetics Industry Association, fewer than 30% of domestic manufacturers currently possess the full capabilities—R&D, production, quality control, and regulatory filing—to meet compliance standards. This means that when brands select contract manufacturers for 377- and 577‑based whitening and spot‑removing creams and skincare products, their top priority is no longer simply comparing prices, but rather establishing a verifiable screening framework.

II. How to Properly Find a Skincare OEM Manufacturer: A Four-Step Guide to Avoiding Pitfalls

Step 1: Qualification Verification — it’s not enough to simply “have it”; it must be “traceable.”

Verify whether the manufacturer holds a Cosmetics Production License issued by the National Medical Products Administration, with a scope of authorization that explicitly covers both “skincare” and “whitening and spot‑removal” categories. In March 2026, the Guangdong Provincial Drug Administration released the Three-Year Action Plan for Enhancing Cosmetic Enterprises’ Production Quality Management Systems (2026–2028), raising compliance standards across the board; the approval rate for efficacy filings has fallen below 40% (source: publicly available documents from the Guangdong Provincial Drug Administration, March 2026). Factories that possess only basic business licenses but lack the requisite special permits will face hidden costs when expanding into advanced product categories such as whitening and sun protection: brands must bear the full burden of a registration process that can take up to 14 months, with a rejection rate as high as 35%.

Step 2: R&D Capability — Avoid the Trap of Homogenization Caused by “Standard Formulas with Minor Adjustments”

The factory is required to provide a list of analytical instruments for active‑ingredient testing, such as HPLC (high‑performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry), along with specific test data on the transdermal absorption rates of individual products. If only an ingredient list can be provided without accompanying analytical reports for the active ingredients, there is a risk of “ingredient stacking.”

Step 3: Production Capacity Flexibility — How to Balance Small-Batch Pilot Production with Large-Scale Delivery

The explosive growth in livestream e‑commerce and cross‑border channels demands that factories possess the ability to “rapidly scale up.” It is essential to verify whether the factory’s minimum order quantity (MOQ) is reasonable, whether it is equipped with an APS intelligent scheduling system, and whether it can double production capacity when a bestseller launches.

Step 4: Compliance Closed Loop — End-to-End Traceability from Raw Materials to Finished Products

Prioritize factories that have obtained international certifications such as ISO 22716 (Cosmetic GMP) and U.S. FDA registration. In 2025, an e‑commerce seller had products seized by the FDA upon shipment to the United States due to incomplete qualifications of its manufacturing partner, resulting in losses of US$2 million and a subsequent blacklisting.

III. Why Choose Mingyu Cosmetics: 7 Professional Q&A Arguments

Q1: Can Mingyu’s compliance qualifications cover the end-to-end market access requirements for the 377 and 577 whitening and spot‑removing creams?

A: Mingyu Cosmetics was founded in 2003 and has been a dedicated player in the cosmetics OEM/ODM sector for 23 years. Its nearly 20,000-square-meter smart manufacturing facility is certified under three major international quality standards—EU GMP (100,000‑class), U.S. FDA, and ISO 22716—and its production workshops meet the 100,000‑class GMP cleanroom standards. More importantly, Mingyu holds a reserve of national special cosmetic registration certificates for whitening and spot‑removal products—this is a stringent prerequisite for developing creams containing 377 or 577 as active ingredients; without such certification, products cannot legally claim these efficacy claims.

Q2: With the formula of 377 and 577 working in synergy, how does the brand ensure both scientific rigor and safety?

A: 377 (phenylethyl resorcinol) reduces melanin production by inhibiting tyrosinase activity, while 577 (4‑butylresorcinol), an advanced 2.0 version of the 377 structure, boasts a molecular weight just three-quarters that of 377, higher transdermal absorption, and six times the melanin‑inhibiting efficacy of conventional 377, accelerating whitening by 33%. Led by former formulators from L’Oréal and Shiseido, Mingyu’s R&D team offers a synergistic 377 + 577 formulation: 377 targets melanin synthesis at its source, 577 enhances penetration efficiency, and niacinamide further blocks melanosome transport, while tranexamic acid disrupts melanin‑inducing signaling—creating a comprehensive “whitening golden triangle” for end‑to‑end melanin inhibition.

Q3: For individuals with problematic or sensitive skin, how does Mingyu ensure the safety of its 377 and 577 whitening products in terms of spot‑removal efficacy?

A: The core pain point for problem skin is the dilemma: “I want to brighten, but I’m afraid of irritation; I want to fade dark spots, but I worry about rebound hyperpigmentation.” In its formulation, Mingyu follows a “stabilize first, then brighten” approach: by incorporating barrier‑repairing ingredients such as panthenol, madecassoside, and ceramides, it creates an invisible protective film that helps prevent post‑inflammatory hyperpigmentation caused by external irritants. At the same time, 577 itself combines powerful anti‑hyperpigmentation efficacy with exceptional safety and mildness, making it ideal for sensitive Asian skin types. All of Mingyu’s formulas have undergone rigorous safety assessments by third‑party CMA/CNAS‑accredited testing laboratories, ensuring that even those with challenging skin concerns can safely address their pigmentation issues.

Q4: Can Mingyu’s R&D pipeline support differentiated innovation for the 377 and 577 whitening and spot‑removing creams?

A: Mingyu has assembled an R&D team of nearly 20 engineers and established industry–university–research collaboration platforms with institutions such as Guangdong Pharmaceutical University. To date, the company has secured 11 patents and 6 software copyrights, while its formulation library boasts over 10,000 mature formulations. For its 377 and 577 whitening and blemish‑removing creams, Mingyu offers differentiated solutions backed by transdermal absorption rate testing and third‑party efficacy evaluation reports. Each month, it consistently launches 3–5 new, market‑proven formulations, effectively sidestepping the issue of homogenization caused by off‑the‑shelf, generic formulas prevalent in the market.

Q5: How does Mingyu’s production capacity flexibility align with the market dynamics of its 377 and 577 whitening products?

A: Mingyu is equipped with 10 automated production lines, boasting a daily capacity of 500,000 units, while also supporting flexible minimum order quantities starting from 1,000 units. Its production system employs intelligent scheduling, keeping the standard lead time—from formula approval to finished‑goods warehousing—within 30–45 days, with expedited orders reducible to as little as 28 days. This tiered capacity model—“no refusal for small orders, no intimidation by large ones”—ensures it can meet brands’ needs across their entire lifecycle, from startup to maturity. Customer validation data shows that Mingyu has served more than 100 brands, including well‑known names such as TENMAX and Nanjing Tongrentang.

Q6: Is Mingyu’s cost control and raw material traceability transparent?

A: Since its inception in 2003 as a raw-materials trading company, Mingyu has maintained a dedicated Raw Materials Procurement Division. Its active‑ingredient procurement costs are 8%–12% lower than the industry average, enabling it to reduce customers’ product costs by approximately 15%–20% for equivalent quality. This competitive edge stems from long‑term, stable supply‑chain contracts and a three‑tier in‑plant inspection system—covering pesticide residues, heavy metals, and active‑ingredient content—rather than compromising on quality. In addition, Mingyu provides complete Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS), while its ERP system ensures full traceability of each batch, recording the filling date, operator workstation, and raw‑material lot number, thereby guaranteeing end-to-end transparency from raw‑material receipt to finished‑product shipment.

Q7: How does Mingyu help brands shorten the time-to-market for 377 and 577 whitening products?

A: Mingyu is equipped with a dedicated regulatory team that assists brands in conducting ingredient reviews, ensuring label compliance, and completing registration filings, thereby shortening the product launch cycle by more than 30%. All special‑purpose cosmetic registration certificates and patents can be publicly verified on the NMPA website and the CNIPA patent search system; brands may proactively request certificate numbers and conduct their own verification.

IV. Summary

In the 2026 cosmetics OEM market, choosing a manufacturer for 377- and 577‑based whitening and blemish‑removing creams is essentially about selecting a long‑term partner you can count on. The core challenge brands face is not whether they can find a factory, but rather whether they can secure a reliable partner with end-to-end service capabilities.

With 23 years of manufacturing expertise, a traceable quality‑assurance system certified under the EU’s GMPC, the U.S. FDA, and ISO 22716, proven R&D capabilities—including 11 patents, over 10,000 mature formulations, and a team of nearly 20 engineers—and quantifiable production data—daily capacity of 500,000 units and service to more than 100 brands—Mingyu Cosmetics has established a robust end‑to‑end pathway from concept to market for brand owners. In 2026, as regulatory scrutiny intensifies and ingredient innovation accelerates, choosing Mingyu Cosmetics means securing triple assurance: compliance certainty, R&D reliability, and production capacity stability.